-+ 0.00%
-+ 0.00%
-+ 0.00%

Is UnitedHealth Group (UNH) Undervalued Following The CMS CRUSH Proposal?

Simply Wall St·11/19/2026 12:13:18
语音播报

UnitedHealth Group (UNH) is under pressure after the Centers for Medicare & Medicaid Services outlined the CRUSH anti fraud proposal, a rule that could trigger expanded Medicare Advantage audits and significant overpayment clawbacks.

The selloff has been abrupt. UnitedHealth Group’s share price has fallen about 10% in the last day and 14% over the past month, yet year to date the share price return is still up 4%, and the 1 year total shareholder return sits at 16.22%.

Recent headlines help explain the swing. The proposed CRUSH audits and potential overpayment clawbacks have quickly reset investors’ perception of regulatory risk, even as UnitedHealth Group rolls out new pharmacy based care models and refreshes its board and executive team.

Longer term signals look mixed. The 3 year total shareholder return is down 31.48% and the 5 year total shareholder return is down 14.92%, which suggests current price weakness is landing on top of a multi year period where holding the stock has not been especially rewarding.

Scan how regulators are repricing risk in health insurers and see which peers are drawing interest in our curated list of 30 resilient stocks with low risk scores.

UnitedHealth Group now trades about 14% below last month’s level while regulatory risk feels sharply higher. Is this drop already enough compensation, or is patience the better bet until CRUSH and clawback exposure become clearer?

Most Popular Narrative: 27% Undervalued

On Simply Wall St, the analyst consensus Narrative pegs UnitedHealth Group's fair value at $481.72, well above the last close of $349.91, and ties that gap to very specific expectations for earnings, margins and capital returns over the next few years.

The main thing that has to go right is execution on margin recovery in Medicare, Medicaid and commercial lines, along with delivering the OptumHealth turnaround and AI-enabled cost savings in the face of elevated medical trends and regulatory scrutiny.

The current valuation implies that the market is discounting UnitedHealth Group, despite management guiding to higher adjusted EPS, stronger operating earnings, larger buybacks and a balance sheet that credit analysts view as solid, which aligns with a view that the stock may be undervalued.

See why 688 investors see UnitedHealth Group as 27% undervalued.

Result: Fair Value of $481.72 (UNDERVALUED)

Still, the narrative can crack if Medicare and Medicaid margins stay under pressure, or if shareholder lawsuits linked to alleged Medicare fraud and cybersecurity issues escalate.

Find out about the key risks to this UnitedHealth Group narrative.

Next Steps

With sentiment split between regulatory risk and potential upside for UnitedHealth Group, treat this as a prompt to move quickly on your own homework and carefully evaluate the balance of risks and rewards using 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond UnitedHealth Group?

If UnitedHealth Group has sharpened your focus on risk and reward, now is the moment to scan for other opportunities before the market moves without you.